Literature DB >> 29085786

The 2016 Revision to the World Health Organization Classification of Myelodysplastic Syndromes.

Ming Hong1, Guangsheng He1.   

Abstract

Entities:  

Year:  2017        PMID： 29085786      PMCID： PMC5655460          DOI： 10.1515/jtim-2017-0002

Source DB:  PubMed          Journal:  J Transl Int Med        ISSN： 2224-4018


× No keyword cloud information.
  18 in total

1.  TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

Authors:  Martin Jädersten; Leonie Saft; Alexander Smith; Austin Kulasekararaj; Sabine Pomplun; Gudrun Göhring; Anette Hedlund; Robert Hast; Brigitte Schlegelberger; Anna Porwit; Eva Hellström-Lindberg; Ghulam J Mufti
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

2.  Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts.

Authors:  Mrinal M Patnaik; Curtis A Hanson; Nanna H Sulai; Janice M Hodnefield; Ryan A Knudson; Rhett P Ketterling; Terra L Lasho; Ayalew Tefferi
Journal:  Blood       Date:  2012-04-26       Impact factor: 22.113

3.  Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression.

Authors:  Catherine A Cargo; Nicola Rowbotham; Paul A Evans; Sharon L Barrans; David T Bowen; Simon Crouch; Andrew S Jack
Journal:  Blood       Date:  2015-09-21       Impact factor: 22.113

4.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

5.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

6.  Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.

Authors:  Rafael Bejar; Kristen E Stevenson; Bennett Caughey; R Coleman Lindsley; Brenton G Mar; Petar Stojanov; Gad Getz; David P Steensma; Jerome Ritz; Robert Soiffer; Joseph H Antin; Edwin Alyea; Philippe Armand; Vincent Ho; John Koreth; Donna Neuberg; Corey S Cutler; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2014-08-04       Impact factor: 44.544

7.  Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.

Authors:  Mar Mallo; Mónica Del Rey; Mariam Ibáñez; M José Calasanz; Leonor Arenillas; M José Larráyoz; Carmen Pedro; Andrés Jerez; Jaroslaw Maciejewski; Dolors Costa; Meritxell Nomdedeu; María Diez-Campelo; Eva Lumbreras; Teresa González-Martínez; Isabel Marugán; Esperanza Such; José Cervera; Juan C Cigudosa; Sara Alvarez; Lourdes Florensa; Jesús M Hernández; Francesc Solé
Journal:  Br J Haematol       Date:  2013-04-25       Impact factor: 6.998

Review 8.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

Review 9.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

10.  TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.

Authors:  Rafael Bejar; Allegra Lord; Kristen Stevenson; Michal Bar-Natan; Albert Pérez-Ladaga; Jacques Zaneveld; Hui Wang; Bennett Caughey; Petar Stojanov; Gad Getz; Guillermo Garcia-Manero; Hagop Kantarjian; Rui Chen; Richard M Stone; Donna Neuberg; David P Steensma; Benjamin L Ebert
Journal:  Blood       Date:  2014-09-15       Impact factor: 22.113
View more
  12 in total

1.  The predictive value of PNH clones, 6p CN-LOH, and clonal TCR gene rearrangement for aplastic anemia diagnosis.

Authors:  Yash B Shah; Salvatore F Priore; Yimei Li; Chi N Tang; Peter Nicholas; Peter Kurre; Timothy S Olson; Daria V Babushok
Journal:  Blood Adv       Date:  2021-08-24

2.  Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization for detecting chromosome abnormalities in myelodysplastic syndromes: A retrospective study.

Authors:  Xiaofei Ai; Bing Li; Zefeng Xu; Jinqin Liu; Tiejun Qin; Qinghua Li; Zhijian Xiao
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

3.  Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis.

Authors:  Teng Gao; Ryan Ptashkin; Kelly L Bolton; Maria Sirenko; Christopher Fong; Barbara Spitzer; Kamal Menghrajani; Juan E Arango Ossa; Yangyu Zhou; Elsa Bernard; Max Levine; Juan S Medina Martinez; Yanming Zhang; Sebastià Franch-Expósito; Minal Patel; Lior Z Braunstein; Daniel Kelly; Mariko Yabe; Ryma Benayed; Nicole M Caltabellotta; John Philip; Ederlinda Paraiso; Simon Mantha; David B Solit; Luis A Diaz; Michael F Berger; Virginia Klimek; Ross L Levine; Ahmet Zehir; Sean M Devlin; Elli Papaemmanuil
Journal:  Nat Commun       Date:  2021-01-12       Impact factor: 17.694

4.  Comprehensive analysis of genetic factors predicting overall survival in Myelodysplastic syndromes.

Authors:  Nehakumari Maurya; Purvi Mohanty; Somprakash Dhangar; Purvi Panchal; Farah Jijina; S Leo Prince Mathan; Chandrakala Shanmukhaiah; Manisha Madkaikar; Babu Rao Vundinti
Journal:  Sci Rep       Date:  2022-04-08       Impact factor: 4.379

5.  Association of Somatic Gene Mutations with Risk of Transformation into Acute Myeloid Leukemia in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Noorwati Sutandyo; Resti Mulyasari; Agus Kosasih; Ikhwan Rinaldi; Melva Louisa; Andi Putra Kevinsyah; Kevin Winston
Journal:  Asian Pac J Cancer Prev       Date:  2022-04-01

6.  Cytogenetic characteristics in Vietnamese patients diagnosed with primary myelodysplastic syndromes.

Authors:  Minh Phuong Vu; Hong Quang Ha; Cuc Nhung Nguyen
Journal:  Leuk Res Rep       Date:  2022-08-12

7.  Low-risk myelodysplastic syndrome managed with an erythroid-stimulating agent for 10 years.

Authors:  Anthony Esparza; Raj Chandra Singaraju; Joseph Paul Happel
Journal:  BMJ Case Rep       Date:  2020-04-06

8.  Chronic Neutrophilic Leukemia with Monocytosis.

Authors:  Laila Alromaih; Leena Abdalla; Arifa Jamal; Assim Osman; Mohanad Bakkar; Lina Abdul Samad; Tamer M Ahmed
Journal:  Eur J Case Rep Intern Med       Date:  2021-05-26

9.  A novel automated image analysis system using deep convolutional neural networks can assist to differentiate MDS and AA.

Authors:  Konobu Kimura; Yoko Tabe; Tomohiko Ai; Ikki Takehara; Hiroshi Fukuda; Hiromizu Takahashi; Toshio Naito; Norio Komatsu; Kinya Uchihashi; Akimichi Ohsaka
Journal:  Sci Rep       Date:  2019-09-16       Impact factor: 4.379

10.  Azacitidine Omega-3 Self-Assemblies: Synthesis, Characterization, and Potent Applications for Myelodysplastic Syndromes.

Authors:  Milad Baroud; Elise Lepeltier; Yolla El-Makhour; Nolwenn Lautram; Jerome Bejaud; Sylvain Thepot; Olivier Duval
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.